Lung Cancer Therapeutics, Industry - Market Forecast 2016-25, Global Research, Challenges, Analysis, Share, Trends
"Global
Lung Cancer Therapeutics Market 2016-2020"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
About
Lung Cancer Therapeutics
Lung
cancer is a common cause of mortality and morbidity in both developed
and developing countries. Smoking is a major cause of lung cancer,
though it also occurs in non-smokers. Lung cancer can be categorized
into two major types, namely NSCLC and SCLC. NSCLC is the commonest
type of lung cancer and constitutes almost 85%-90% of the total
diagnosed cases. It grows and spreads quite slowly.
Technavios
analysts forecast the global lung cancer therapeutics market to
contribute around $11.19 billion during the period 2016-2020.
Covered
in this report
The
report covers the present scenario and the growth prospects of the
global lung cancer therapeutics market for 2016-2020. To calculate
the market size, the report considers the revenue generated from the
sales of branded and generic drugs used to treat and prevent lung
cancer therapeutics. The report also considers the revenues to be
generated from the sales of drugs that are expected to be launched
into the market along with the decline in revenues from the
genericization of the marketed drugs during the forecast period.
The
market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's
report, Global Lung Cancer Therapeutics Market 2016-2020, has been
prepared based on an in-depth market analysis with inputs from
industry experts. The report covers the market landscape and its
growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.
Key
vendors
F.
Hofmann-La Roche
Eli
Lilly
AstraZeneca
Pfizer
Celgene
Other
prominent vendors
Abbvie
Aetna
Agennix
Allergan
Amgen
ARIAD
Pharmaceuticals
Astellas
Pharma
Betta
Pharmaceuticals
BeyondSpring
Pharmaceuticals
BioNumerik
Pharmaceuticals
Boehringer
Ingelheim
Boston
Biomedical
Bristol-Myers
Squibb
Celldex
CTI
BioPharma
Eisai
GlaxoSmithKline
GTx
Helsinn
Hutchison
Medipharma
Ionis
Pharmaceuticals
Kadmon
Corporation
MabVax
Merck
Novartis
NovaRx
Corporation
OncoGeneX
Ono
Pharmaceutical
OSE
Immunotherapeutics
OSI
Pharmaceuticals
Peregrine
PharmaMar
Pierre
Fabre
Qiagen
Recombio
Samsung
Bioepis
Sanofi
SFJ
Pharmaceuticals
Spectrum
Pharmaceuticals
Sumitomo
Dainippon Pharma
Synta
Takeda
Pharmaceuticals
Teva
Pharmaceutical
Xcovery
Market
driver
Growing
demand for targeted therapies
For
a full, detailed list, view our report
Market
challenge
Growing
popularity of alternative therapeutics
For
a full, detailed list, view our report
Market
trend
Emergence
of nanomedicine platform for the treatment of lung cancer
For
a full, detailed list, view our report
Key
questions answered in this report
What
will the market size be in 2020 and what will the growth rate be?
What
are the key market trends?
What
is driving this market?
What
are the challenges to market growth?
Who
are the key vendors in this market space?
What
are the market opportunities and threats faced by the key vendors?
Comments
Post a Comment